William Blair Has Negative Forecast for CeriBell Q1 Earnings

CeriBell (NASDAQ:CBLL) – William Blair decreased their Q1 2025 earnings per share estimates for CeriBell in a report released on Wednesday, February 26th. William Blair analyst M. Andrew now expects that the company will post earnings of ($0.44) per share for the quarter, down from their prior estimate of ($0.30). William Blair has a “Outperform” rating on the stock. The consensus estimate for CeriBell’s current full-year earnings is ($2.46) per share. William Blair also issued estimates for CeriBell’s Q2 2025 earnings at ($0.46) EPS, Q3 2025 earnings at ($0.45) EPS, Q4 2025 earnings at ($0.45) EPS, FY2025 earnings at ($1.81) EPS, Q1 2026 earnings at ($0.37) EPS, Q2 2026 earnings at ($0.35) EPS, Q3 2026 earnings at ($0.35) EPS, Q4 2026 earnings at ($0.33) EPS and FY2026 earnings at ($1.40) EPS.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.08). The firm had revenue of $18.53 million during the quarter, compared to analysts’ expectations of $17.55 million.

Other equities analysts have also recently issued research reports about the stock. JPMorgan Chase & Co. initiated coverage on shares of CeriBell in a research note on Tuesday, November 5th. They issued an “overweight” rating and a $32.00 price objective on the stock. Canaccord Genuity Group reiterated a “buy” rating and set a $33.00 price target on shares of CeriBell in a research note on Wednesday. Bank of America began coverage on CeriBell in a report on Tuesday, November 5th. They issued a “buy” rating and a $32.00 target price on the stock. Canaccord Genuity Group began coverage on CeriBell in a research note on Tuesday, November 5th. They issued a “buy” rating and a $30.00 price objective on the stock. Finally, TD Cowen raised their target price on shares of CeriBell from $31.00 to $36.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, CeriBell presently has a consensus rating of “Buy” and an average price target of $32.60.

CeriBell Price Performance

Shares of CBLL opened at $23.83 on Friday. CeriBell has a one year low of $18.69 and a one year high of $32.75. The business has a fifty day moving average price of $23.34.

Institutional Trading of CeriBell

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Woodline Partners LP purchased a new position in shares of CeriBell during the 4th quarter worth about $2,588,000. Yu Fan purchased a new position in shares of CeriBell during the 4th quarter worth about $31,631,000. TPG GP A LLC bought a new stake in shares of CeriBell in the 4th quarter valued at about $102,677,000. RTW Investments LP bought a new stake in shares of CeriBell in the 4th quarter valued at about $3,882,000. Finally, Red Tree Management LLC bought a new position in shares of CeriBell during the 4th quarter worth approximately $57,083,000.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.